112 related articles for article (PubMed ID: 15745897)
1. Seizures associated with memantine use.
Peltz G; Pacific DM; Noviasky JA; Shatla A; Mehalic T
Am J Health Syst Pharm; 2005 Feb; 62(4):420-1. PubMed ID: 15745897
[No Abstract] [Full Text] [Related]
2. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
3. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for dementia associated with Parkinson's disease.
Morgan J; Sethi KD
Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
[No Abstract] [Full Text] [Related]
5. Nightmares and memantine: a case report and review of literature.
Iraqi A; Hughes TL
J Am Med Dir Assoc; 2009 Jan; 10(1):77-8. PubMed ID: 19111861
[No Abstract] [Full Text] [Related]
6. [Are anti-dementia drugs worthwhile?].
Lang CJ
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():85-9. PubMed ID: 17955784
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial of memantine in primary progressive aphasia.
Johnson NA; Rademaker A; Weintraub S; Gitelman D; Wienecke C; Mesulam M
Alzheimer Dis Assoc Disord; 2010; 24(3):308. PubMed ID: 20798612
[No Abstract] [Full Text] [Related]
8. Memantine Exacerbates Corrected QT Interval Prolongation in Alzheimer's Disease: A Case Report from an Unintentional Rechallenge.
Kajitani K; Yanagimoto K; Monji A; Maruyama T
J Am Geriatr Soc; 2016 Jan; 64(1):232-3. PubMed ID: 26782892
[No Abstract] [Full Text] [Related]
9. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
Prasher VP; Sachdeva N; Adams C; Haque MS
Int J Geriatr Psychiatry; 2013 Feb; 28(2):219-20. PubMed ID: 23296840
[No Abstract] [Full Text] [Related]
10. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Borah B; Sacco P; Zarotsky V
Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
Stevens DL; Lee MR; Padua Y
Pharmacotherapy; 2008 Mar; 28(3):403-5. PubMed ID: 18294120
[TBL] [Abstract][Full Text] [Related]
13. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
14. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Lee JH; Sevigny J
Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
17. Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Hsu YC; Chao CY; Chang HA; Hwang SY; Tzeng NS
J Neuropsychiatry Clin Neurosci; 2013; 25(2):E25-6. PubMed ID: 23686050
[No Abstract] [Full Text] [Related]
18. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
19. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
20. [Current strategies of pathogenetic therapy of Alzheimer's disease].
Gavrilova SI; Zharikov GA
Vestn Ross Akad Med Nauk; 2001; (7):13-8. PubMed ID: 11523421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
